US mRNA Synthesis & Manufacturing Market (2024-2029)
The US mRNA Synthesis & Manufacturing Market was valued at $496.89 Million in 2024 and projected to reach to $630.73 Million by 2029, representing a compound annual growth rate of 4.9%. The US mRNA synthesis and manufacturing market is positioned for sustained growth through 2029, driven by expanding pipelines of mRNA-based vaccines and therapeutics across oncology, immunology, and infectious disease sectors.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US mRNA Synthesis & Manufacturing Market Trends and Insights
- The US market benefits from advanced biopharmaceutical infrastructure, significant investment in mRNA-based therapeutics, and a robust regulatory framework that supports innovation in vaccine and therapeutic development.
- Leading US biotech companies and contract manufacturing organizations (CMOs) are expanding production capacity to meet growing demand for mRNA-based treatments. In 2024, the US dominates the global mRNA synthesis landscape, driven by established manufacturing capabilities and a strong pipeline of mRNA candidates in clinical development.
- By 2029, the US market is expected to capture increased market share as companies scale manufacturing operations and commercialize next-generation mRNA therapies.
- The growth trajectory reflects heightened investment in manufacturing infrastructure, technological advancements in synthesis processes, and accelerating adoption of mRNA platforms across oncology, infectious disease, and rare genetic disorders..
Key Market Statistics
- CAGR (2024-2029) 4.9% CAGR
- Market Size, 2024 ~USD 496.89 Million
- Forecast, 2029 ~USD 630.73 Million
- Country US
US mRNA Synthesis & Manufacturing Market Overview
Market Valuation :
The US mRNA synthesis and manufacturing market reached $496.89 million in 2024, with projected growth to $630.73 million by 2029, representing a steady 4.9% CAGR driven by increased therapeutic development and vaccine innovation.
Advanced Infrastructure :
The US benefits from world-leading biopharmaceutical manufacturing capabilities, established contract manufacturing organizations (CMOs), and state-of-the-art facilities that support large-scale mRNA production and quality assurance.
Investment & Innovation :
Significant venture capital and government funding flow into US-based mRNA companies, accelerating development of next-generation therapeutics for oncology, infectious diseases, and personalized medicine applications.
Regulatory Support :
The FDA's streamlined approval pathways and clear regulatory guidance for mRNA therapeutics provide US manufacturers with competitive advantages in bringing novel treatments to market faster than international competitors.
US mRNA Synthesis & Manufacturing Market Dynamics
- Increasing adoption of personalized medicine and combination therapies will fuel demand for flexible, scalable manufacturing solutions.
- Investment in domestic production capacity, supported by government initiatives to strengthen biodefense and reduce supply chain vulnerabilities, will further accelerate market expansion.
- The competitive landscape will intensify as established pharmaceutical companies and emerging biotech firms scale manufacturing capabilities to meet growing clinical and commercial demand..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Analytical And Scientific Instrumentation
- Environmental Testing
- Gas Chromatography
- Polymerase Chain Reaction (PCR)
- Automated Liquid Handling Systems
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Shimadzu Corporation
- Merck KGaA
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- SANOFI
- Merck KGaA
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- The US mRNA synthesis & manufacturing market is valued at $496.89M in 2024 and will reach $630.73M by 2029, growing at 4.9% CAGR.
- US market leadership is driven by advanced biopharmaceutical infrastructure, substantial R&D investment, and a supportive regulatory environment for mRNA therapeutics.
- Expansion of manufacturing capacity by US biotech firms and CMOs is accelerating to support the growing pipeline of mRNA-based vaccines and therapies.
- The US market is benefiting from diversification of mRNA applications beyond infectious disease into oncology and rare genetic disorders through 2029.
mRNA Synthesis & Manufacturing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MRNA SYNTHESIS & MODIFICATION SERVICES (Service) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 2.23 (2024) |
| Revenue Forecast (Billions) | ~USD 2.96 (2029) |
| Segments Covered | Product, Type, Application, End User, Service, Consumables, Transcription Consumables, Purification Consumables, Analysis & Characterization Consumables |
US mRNA Synthesis & Manufacturing Market Report Segmentation
9 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Type
- Analysis & Characterization Consumables
- Analysis Kits And Reagents
- Chromatography Filters & Membrane
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Products
- Other Purification Consumables
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Purification Consumables
- Purification Kits & Reagents
- Rna Polymerases
- Transcription Consumables
- Vectors
By Application
- Cell & Gene Therapies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutions
- Cros & Cdmos
- Cros And Cdmos
- Pharmaceutical & Biotechnology Companies
- Small-Scale Cros & Cdmos
By Service
- Manufacturing & Scale-Up Services
- Mrna Analysis & Characterization Services
- Mrna Purification Services
- Mrna Synthesis & Modification Services
By Consumables
- Analysis & Characterization Consumables
- Purification Consumables
- Transcription Consumables
By Transcription Consumables
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Rna Polymerases
- Vectors
By Purification Consumables
- Chromatography Filters & Membranes
- Other Purification Consumables
- Purification Kits & Reagents
- Purification Kits And Reagents
By Analysis & Characterization Consumables
- Analysis Kits & Reagents
- Analysis Kits And Reagents
- Other Analysis & Characterization Consumables
US: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 180.3 | 132.2 | 133 | 137.7 | 144.5 | 151.6 | 159.1 | 169.1 | 4.9 |
| CROS & CDMOS | 151 | 110.6 | 111.2 | 115.1 | 120.7 | 126.5 | 132.6 | 140.9 | 4.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 425.1 | 312.1 | 314.7 | 326.4 | 343.1 | 360.6 | 379 | 403.5 | 5.1 |
| TOTAL | 756.5 | 554.8 | 558.9 | 579.2 | 608.3 | 638.8 | 670.7 | 713.4 | 5 |
US: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 80.9 | 70.3 | 71 | 74.3 | 79.3 | 85.2 | 92 | 101.4 | 7.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 230.5 | 201.1 | 204 | 214.3 | 229.5 | 247.5 | 268.6 | 297 | 7.8 |
| SMALL-SCALE CROS & CDMOS | 27.4 | 23.6 | 23.6 | 24.5 | 26 | 27.7 | 29.6 | 32.4 | 6.5 |
| TOTAL | 338.8 | 295 | 298.7 | 313.1 | 334.8 | 360.3 | 390.2 | 430.7 | 7.6 |
Target Audience
- Biopharmaceutical Manufacturers : US-based and international pharma companies need detailed market intelligence to guide mRNA manufacturing investments, capacity planning, and strategic partnerships within the competitive US landscape.
- Contract Manufacturing Organizations (CMOs) : CMOs and specialized manufacturers require market forecasts and demand projections to optimize facility investments, service offerings, and client acquisition strategies in the growing US mRNA sector.
- Venture Capital & Private Equity Firms : Investment firms evaluating mRNA technology companies and manufacturing platforms need comprehensive US market data to assess growth potential, valuation benchmarks, and exit opportunities.
- Healthcare Policy & Government Agencies : US regulatory bodies and policy makers require market analysis to inform biodefense initiatives, domestic manufacturing incentives, and strategic decisions on supply chain resilience and innovation support.
- Technology & Equipment Suppliers : Manufacturers of mRNA synthesis equipment, bioreactors, and quality control systems need market insights to identify customer segments, forecast demand, and develop solutions aligned with US manufacturing growth.
Reasons to Buy this Report
- Market Size & Growth Projections : Access precise valuation data for the US market ($496.89M in 2024) with detailed forecasts through 2029, enabling accurate financial planning and investment decisions for mRNA manufacturing ventures.
- Competitive Landscape Intelligence : Understand the positioning of US-based mRNA manufacturers, CMOs, and technology providers to identify partnership opportunities, acquisition targets, and competitive differentiation strategies in a rapidly consolidating market.
- Regulatory & Infrastructure Insights : Gain detailed analysis of FDA approval pathways, manufacturing standards, and facility requirements specific to the US market, reducing compliance risks and accelerating time-to-market for new mRNA products.
- Investment & Funding Trends : Identify emerging funding patterns, government incentives, and capital allocation trends in the US mRNA sector to guide investment strategies and partnership development with well-funded innovators.
- Demand Drivers & Application Opportunities : Discover high-growth therapeutic areas and clinical applications driving US market demand, from personalized oncology treatments to infectious disease vaccines, to prioritize R&D and commercialization efforts.
Frequently asked questions
What is the current size of the US mRNA synthesis & manufacturing market?
The US mRNA synthesis & manufacturing market was valued at $496.89 million in 2024 and is expected to reach $630.73 million by 2029.
What is the growth rate of the US mRNA synthesis & manufacturing market?
The US market is projected to grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2029.
What factors are driving growth in the US mRNA synthesis market?
Key drivers include expanding manufacturing capacity, increasing mRNA therapeutic pipelines, regulatory support, investment in infrastructure, and diversification into oncology and rare disease applications.
Which segments are contributing most to US mRNA synthesis market growth?
Growth is driven by vaccine development, therapeutic mRNA platforms, contract manufacturing services, and synthesis technology providers serving US biopharmaceutical companies.
How does the US market compare to the global mRNA synthesis market?
The US represents a significant portion of the global market, with established infrastructure and leadership in mRNA innovation, while the global market grows at 5.8% CAGR compared to the US rate of 4.9%.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the mRNA synthesis and manufacturing market. Exhaustive secondary research was done to collect information on the mRNA synthesis and manufacturing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as market share analysis, MnM repository analysis, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the mRNA synthesis and manufacturing market.
Secondary Research
The market for the companies offering mRNA synthesis and manufacturing solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product & service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and product-oriented perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global mRNA synthesis and manufacturing market scenario. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical & biopharmaceutical industry) and the supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, as well as channels) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, and online, personal, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down approache was used to estimate and validate the total size of the mRNA synthesis and manufacturing market. These methods include market share analysis, MnM repository analysis were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the mRNA synthesis and manufacturing market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
mRNA synthesis and manufacturing refers to the process of producing messenger RNA (mRNA) through in vitro transcription, followed by various purification, and characterization steps to create high-quality mRNA products suitable for research, therapeutic, or vaccine applications. The mRNA synthesis and manufacturing market encompasses the development, production, and commercialization of messenger RNA (mRNA) products, including their synthesis via in vitro transcription, large-scale manufacturing, and formulation. This market serves various applications such as vaccines, therapeutic treatments, and potentially other areas like protein replacement. It involves specialized technologies and equipment, adherence to regulatory standards, and a global supply chain network.
The study provides an in-depth analysis of the mRNA synthesis and manufacturing market based on contemporary market trends and developments, and its potential growth from 2024 to 2029. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key mRNA synthesis and manufacturing product and service providers.
Stakeholders
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Raw Material Suppliers
- Market Research and Consulting Firms
- Regulatory Agencies
- Venture Capitalists
- Government Organizations
- Industry Associations and Professional Societies
Report Objectives
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product, service, application, and region
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product by end user and service by end user
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the mRNA synthesis and manufacturing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global mRNA synthesis and manufacturing market and comprehensively analyze their products and services portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as product/service launches, expansions, agreements, and collaborations in the mRNA synthesis and manufacturing market
- To benchmark players within the mRNA synthesis and manufacturing market using the Company Evaluation Matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full mRNA Synthesis & Manufacturing Market Report
Full forecast, segment splits, and company analysis for all mRNA Synthesis & Manufacturing Market.
- Canada mRNA Synthesis & Manufacturing Market
- Germany mRNA Synthesis & Manufacturing Market
- UK mRNA Synthesis & Manufacturing Market
- France mRNA Synthesis & Manufacturing Market
- Switzerland mRNA Synthesis & Manufacturing Market
- Italy mRNA Synthesis & Manufacturing Market
- Spain mRNA Synthesis & Manufacturing Market
- China mRNA Synthesis & Manufacturing Market
- Japan mRNA Synthesis & Manufacturing Market
- India mRNA Synthesis & Manufacturing Market
- South Korea mRNA Synthesis & Manufacturing Market
- Brazil mRNA Synthesis & Manufacturing Market
- Rest Of Europe mRNA Synthesis & Manufacturing Market
- Rest Of Asia Pacific mRNA Synthesis & Manufacturing Market
- Rest Of Latin America mRNA Synthesis & Manufacturing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
